Advisory committee support for Galleri, a multi-cancer early detection blood test, moves GRAIL closer to a first-of-its-kind FDA clearance in cancer screening.

Investor frustration over Novo's pipeline and strategy comes as the company pursues a turnaround plan that includes cuts to fund expansion.

Lilly's latest China licensing deal deepens its reliance on Chinese biotech for new drug candidates across up to five medicines.

Nine chief executives raised alarms about Europe's declining biotech competitiveness as policy and investment shift toward the US and China.

Positive mid-stage results position Viking among the more closely watched challengers in the obesity drug race.

The agency's demand for another survival study clouds the filing path for tovecimig and drew criticism of the company's regulatory strategy from analysts.

Lilly's dominance in the Medicare weight-loss market underscores the commercial scale of the GLP-1 class.

Overton's confirmation hearing put vaccine policy scrutiny at the center of the FDA's leadership transition.

The push reflects European concern that unresolved pricing tensions with Washington could escalate into tariffs on drug exports.

Klomp, credited with drug-pricing negotiations, moves closer to serving as RFK Jr.'s second-in-command at HHS.

The court's scrutiny of medicine pricing adds pressure on India's government to cap cancer drug costs.

The RNAi specialist's listing adds to a wave of biotech IPOs in 2026.

State data on markups intensifies the Indian debate over price caps on essential medicines and devices.

Early data on CAR-T treatment in stiff person syndrome adds to evidence for cell therapy beyond oncology.

The round underscores continued investor appetite for AI-driven drug discovery platforms.

The assay approval addresses a manufacturing requirement for the cell therapy, with every batch facing further checks after approval.

The failure removes a mid-stage indication from Immunovant's pipeline as it prioritizes other autoimmune targets.

Policy analysis tracks the revised 340B rebate pilot and the second wave of Trump administration drug pricing deals.